Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
72High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07619599CT.gov A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab | — | Not Yet Recruiting | — | — | — |
NCT07541170CT.gov A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) | — | Not Yet Recruiting | — | — | — |
NCT07622186CT.gov A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) | — | Not Yet Recruiting | — | — | — |
NCT07486817CT.gov Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab | — | Recruiting | — | — | — |
NCT07623642CT.gov A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. | — | Not Yet Recruiting | — | — | — |
NCT07639242CT.gov Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07452224CT.gov ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07524257CT.gov Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07365319CT.gov A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. | — | Recruiting | — | — | — |
NCT07420439CT.gov Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease | — | Not Yet Recruiting | — | — | — |
Show 507 more trialsShow fewer
NCT07513376CT.gov A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) | — | Recruiting | — | — | — |
NCT06882174CT.gov This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07360743CT.gov Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels | — | Not Yet Recruiting | — | — | — |
NCT07017829CT.gov GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07361510CT.gov A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) | — | Recruiting | — | — | — |
NCT07485179CT.gov Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records Databases | — | Active Not Recruiting | — | — | — |
NCT06400160CT.gov Clinical Trial of TB511 in Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT07264816CT.gov A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC | — | Recruiting | — | — | — |
NCT07394062CT.gov Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01) | — | Recruiting | — | — | — |
NCT07195695CT.gov Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations | — | Recruiting | — | — | — |
NCT07222566CT.gov Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07063745CT.gov A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion | — | Recruiting | — | — | — |
NCT06405230CT.gov Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT07362459CT.gov A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer. | — | Recruiting | — | — | — |
NCT06908993CT.gov Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated | — | Recruiting | — | — | — |
NCT07223047CT.gov A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies | — | Recruiting | — | — | — |
NCT07218003CT.gov A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 | — | Enrolling By Invitation | — | — | — |
NCT07227168CT.gov A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | — | Recruiting | — | — | — |
NCT07223424CT.gov Patient Preference for Subcutaneous vs. Intravenous Immune Therapy | — | Recruiting | — | — | — |
NCT06793215CT.gov A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06899126CT.gov Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07180862CT.gov A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants | — | Recruiting | — | — | — |
NCT07190248CT.gov A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) | — | Recruiting | — | — | — |
NCT06822543CT.gov A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer) | — | Recruiting | — | — | — |
NCT07178795CT.gov A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC | — | Recruiting | — | — | — |
NCT07160335CT.gov A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors | — | Recruiting | — | — | — |
NCT07111520CT.gov A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT07106827CT.gov A Study of GV20-0251 in Advanced or Refractory Solid Tumors | — | Recruiting | — | — | — |
NCT06951399CT.gov Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07162883CT.gov Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | — | Not Yet Recruiting | — | — | — |
NCT07122687CT.gov IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07130032CT.gov Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade | — | Recruiting | — | — | — |
NCT07098988CT.gov Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC | — | Recruiting | — | — | — |
NCT07046923CT.gov A Study of LY4175408 in Participants With Advanced Cancer | — | Recruiting | — | — | — |
NCT06758401CT.gov This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. | — | Recruiting | — | — | — |
NCT07070518CT.gov Study of GV20-0251 in Participants With Solid Tumor Malignancies | — | Recruiting | — | — | — |
NCT07020221CT.gov A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | — | Recruiting | — | — | — |
NCT06980272CT.gov SSGJ-707 in Advanced Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06745882CT.gov Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC | — | Recruiting | — | — | — |
NCT06902272CT.gov ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06682806CT.gov A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | — | Terminated | — | — | — |
NCT06364917CT.gov DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC | — | Recruiting | — | — | — |
NCT06579196CT.gov Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1 | — | Recruiting | — | — | — |
NCT07207395CT.gov A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation. | — | Recruiting | — | — | — |
NCT06847334CT.gov A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06875310CT.gov A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | — | Recruiting | — | — | — |
NCT06868277CT.gov A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06731270CT.gov Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy | — | Recruiting | — | — | — |
NCT06868732CT.gov Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC | — | Recruiting | — | — | — |
NCT06917079CT.gov BBO-11818 in Adult Subjects With KRAS Mutant Cancer | — | Recruiting | — | — | — |
NCT06731907CT.gov A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) | — | Recruiting | — | — | — |
NCT07353957CT.gov Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06890598CT.gov Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06726265CT.gov Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) | — | Active Not Recruiting | — | — | — |
NCT06772623CT.gov Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | — | Recruiting | — | — | — |
NCT06835569CT.gov A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | — | Recruiting | — | — | — |
NCT06767514CT.gov Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 | — | Recruiting | — | — | — |
NCT06731413CT.gov Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT06939595CT.gov A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer | — | Recruiting | — | — | — |
NCT06789172CT.gov A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors | — | Recruiting | — | — | — |
NCT06754644CT.gov A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC | — | Recruiting | — | — | — |
NCT05669846CT.gov Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC | — | Recruiting | — | — | — |
NCT06712316CT.gov Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer | — | Recruiting | — | — | — |
NCT06687369CT.gov A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) | — | Recruiting | — | — | — |
NCT06632327CT.gov Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06704724CT.gov A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. | — | Terminated | — | — | — |
NCT06627647CT.gov A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC | — | Recruiting | — | — | — |
NCT06422403CT.gov A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers | — | Recruiting | — | — | — |
NCT06635824CT.gov Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | — | Active Not Recruiting | — | — | — |
NCT06698042CT.gov A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) | — | Active Not Recruiting | — | — | — |
NCT06692738CT.gov A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT06644768CT.gov A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations | — | Recruiting | — | — | — |
NCT06711900CT.gov A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06643910CT.gov A Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06607185CT.gov A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06623422CT.gov A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | — | Recruiting | — | — | — |
NCT06558799CT.gov LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT06561386CT.gov A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% | — | Recruiting | — | — | — |
NCT06643117CT.gov Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT06463665CT.gov Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | — | Recruiting | — | — | — |
NCT06561685CT.gov A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT06333951CT.gov Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). | — | Active Not Recruiting | — | — | — |
NCT06430866CT.gov Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) | — | Active Not Recruiting | — | — | — |
NCT06311721CT.gov A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT06452277CT.gov A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) | — | Recruiting | — | — | — |
NCT06538012CT.gov TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer | — | Recruiting | — | — | — |
NCT06219174CT.gov Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO) | — | Suspended | — | — | — |
NCT06545331CT.gov Study of XB010 in Subjects With Solid Tumors | — | Recruiting | — | — | — |
NCT06532149CT.gov ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer | — | Recruiting | — | — | — |
NCT06216301CT.gov LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC | — | Recruiting | — | — | — |
NCT06280196CT.gov A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC | — | Terminated | — | — | — |
NCT06096844CT.gov Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial | — | Recruiting | — | — | — |
NCT06492421CT.gov Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer. | — | Recruiting | — | — | — |
NCT06447662CT.gov A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | — | Recruiting | — | — | — |
NCT06422143CT.gov Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | — | Recruiting | — | — | — |
NCT06472076CT.gov A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) | — | Active Not Recruiting | — | — | — |
NCT06448312CT.gov A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT06045767CT.gov T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06345729CT.gov A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) | — | Recruiting | — | — | — |
NCT06343402CT.gov Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06400472CT.gov A Study of LY4170156 in Participants With Selected Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06159790CT.gov A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT05777603CT.gov Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06228326CT.gov A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | — | Recruiting | — | — | — |
NCT06357533CT.gov Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations | — | Recruiting | — | — | — |
NCT06236438CT.gov Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT06008093CT.gov A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS | — | Active Not Recruiting | — | — | — |
NCT06312137CT.gov A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) | — | Recruiting | — | — | — |
NCT06984588CT.gov A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT06253871CT.gov A Phase 1/1b Study of IAM1363 in HER2 Cancers | — | Recruiting | — | — | — |
NCT05872867CT.gov Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) | — | Unknown | — | — | — |
NCT06348199CT.gov A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05676749CT.gov C-TIL051 in Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT06151574CT.gov Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | — | Active Not Recruiting | — | — | — |
NCT06249854CT.gov Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06246110CT.gov A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC | — | Active Not Recruiting | — | — | — |
NCT05894889CT.gov Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC | — | Active Not Recruiting | — | — | — |
NCT06162221CT.gov Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | — | Recruiting | — | — | — |
NCT06268613CT.gov A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT05338580CT.gov Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors | — | Withdrawn | — | — | — |
NCT06099782CT.gov A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) | — | Active Not Recruiting | — | — | — |
NCT06119581CT.gov A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06170788CT.gov Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) | — | Recruiting | — | — | — |
NCT06077760CT.gov A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) | — | Recruiting | — | — | — |
NCT05689671CT.gov Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma | — | Active Not Recruiting | — | — | — |
NCT05589818CT.gov Pembrolizumab for Advanced NSCLC and PS 2-3 | — | Recruiting | — | — | — |
NCT06205706CT.gov BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06142617CT.gov A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation. | — | Not Yet Recruiting | — | — | — |
NCT06132698CT.gov Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC | — | Recruiting | — | — | — |
NCT05920356CT.gov A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | — | Recruiting | — | — | — |
NCT05709821CT.gov IMM60 and Pembrolizumab in Melanoma and NSCLC | — | Terminated | — | — | — |
NCT06047379CT.gov Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | — | Recruiting | — | — | — |
NCT05899608CT.gov Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | — | Recruiting | — | — | — |
NCT06049212CT.gov Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008) | — | Active Not Recruiting | — | — | — |
NCT05984277CT.gov A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. | — | Active Not Recruiting | — | — | — |
NCT06100796CT.gov Effect of DM on Outcomes and Response Rate in Patients With Advanced NSCLC on ICI | — | Unknown | — | — | — |
NCT06028633CT.gov Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients | — | Not Yet Recruiting | — | — | — |
NCT06022757CT.gov Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) | — | Recruiting | — | — | — |
NCT05877430CT.gov Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | — | Recruiting | — | — | — |
NCT05668650CT.gov Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC | — | Recruiting | — | — | — |
NCT05791097CT.gov Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC. | — | Withdrawn | — | — | — |
NCT05985655CT.gov Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05751187CT.gov Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients | — | Active Not Recruiting | — | — | — |
NCT05834348CT.gov A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | — | Completed | — | — | — |
NCT05789082CT.gov A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation | — | Recruiting | — | — | — |
NCT06212752CT.gov A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension | — | Active Not Recruiting | — | — | — |
NCT05887492CT.gov Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | — | Recruiting | — | — | — |
NCT05705466CT.gov Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT05171062CT.gov Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT05860296CT.gov Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers | — | Terminated | — | — | — |
NCT05501665CT.gov Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | — | Recruiting | — | — | — |
NCT05782361CT.gov POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC | — | Active Not Recruiting | — | — | — |
NCT05816252CT.gov A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003) | — | Active Not Recruiting | — | — | — |
NCT05787587CT.gov A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05570825CT.gov SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05856981CT.gov Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05669430CT.gov A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | — | Recruiting | — | — | — |
NCT06310915CT.gov Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor | — | Unknown | — | — | — |
NCT05775289CT.gov A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05633602CT.gov Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study | — | Active Not Recruiting | — | — | — |
NCT05714553CT.gov NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | — | Terminated | — | — | — |
NCT05469178CT.gov A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene | — | Terminated | — | — | — |
NCT05753722CT.gov A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies | — | Recruiting | — | — | — |
NCT05617313CT.gov Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT05722015CT.gov A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) | — | Active Not Recruiting | — | — | — |
NCT05609968CT.gov Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) | — | Active Not Recruiting | — | — | — |
NCT05492682CT.gov START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | — | Recruiting | — | — | — |
NCT05599789CT.gov Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004) | — | Unknown | — | — | — |
NCT05566223CT.gov CISH Inactivated TILs in the Treatment of NSCLC | — | Withdrawn | — | — | — |
NCT05691829CT.gov Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC | — | Terminated | — | — | — |
NCT05576077CT.gov A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05555732CT.gov Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) | — | Active Not Recruiting | — | — | — |
NCT05653882CT.gov A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05687266CT.gov Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations | — | Active Not Recruiting | — | — | — |
NCT05585034CT.gov Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors | — | Completed | — | — | — |
NCT05579366CT.gov Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | — | Recruiting | — | — | — |
NCT05609578CT.gov Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation | — | Recruiting | — | — | — |
NCT05499390CT.gov AK112 in Advanced Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05493566CT.gov Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05585320CT.gov A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05544929CT.gov A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | — | Active Not Recruiting | — | — | — |
NCT05208762CT.gov A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05581004CT.gov A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05620134CT.gov Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | — | Active Not Recruiting | — | — | — |
NCT05565378CT.gov A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05502237CT.gov Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05549037CT.gov Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC | — | Completed | — | — | — |
NCT05042375CT.gov A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT04638582CT.gov Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT05317858CT.gov Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets | — | Recruiting | — | — | — |
NCT05431270CT.gov Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) | — | Recruiting | — | — | — |
NCT05180799CT.gov A Phase 1/2 Study of BA3071 in Patients With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05393635CT.gov ITIL-168 in Advanced Solid Tumors | — | Withdrawn | — | — | — |
NCT05258279CT.gov Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations | — | Active Not Recruiting | — | — | — |
NCT05383716CT.gov Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT05085028CT.gov A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT05256381CT.gov A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05430009CT.gov Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT05318573CT.gov A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05395052CT.gov FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05186974CT.gov Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) | — | Active Not Recruiting | — | — | — |
NCT04967417CT.gov Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain Metastases | — | Completed | — | — | — |
NCT05311618CT.gov Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | — | Unknown | — | — | — |
NCT05298423CT.gov Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) | — | Active Not Recruiting | — | — | — |
NCT05403554CT.gov A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers | — | Recruiting | — | — | — |
NCT05070247CT.gov A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT05077709CT.gov IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC | — | Completed | — | — | — |
NCT05284539CT.gov Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer | — | Recruiting | — | — | — |
NCT05215574CT.gov Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05269381CT.gov Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05062980CT.gov Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer | — | Terminated | — | — | — |
NCT05226598CT.gov Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) | — | Completed | — | — | — |
NCT05096663CT.gov Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | — | Active Not Recruiting | — | — | — |
NCT05215340CT.gov Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations | — | Active Not Recruiting | — | — | — |
NCT05234606CT.gov A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors | — | Withdrawn | — | — | — |
NCT05082610CT.gov A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT05141357CT.gov A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT04925986CT.gov Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC | — | Terminated | — | — | — |
NCT05098132CT.gov Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers | — | Recruiting | — | — | — |
NCT05194072CT.gov A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05081609CT.gov A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | — | Active Not Recruiting | — | — | — |
NCT04856176CT.gov A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy | — | Terminated | — | — | — |
NCT04998474CT.gov FRAME-001 Personalized Vaccine in NSCLC | — | Unknown | — | — | — |
NCT05128487CT.gov A Study of NDI 1150-101 in Patients With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05117476CT.gov A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05048797CT.gov A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations | — | Active Not Recruiting | — | — | — |
NCT05117242CT.gov Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05078931CT.gov A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients | — | Active Not Recruiting | — | — | — |
NCT04993677CT.gov A Study of SEA-CD40 Given With Other Drugs in Cancers | — | Completed | — | — | — |
NCT04989322CT.gov Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC | — | Unknown | — | — | — |
NCT04677361CT.gov Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab | — | Withdrawn | — | — | — |
NCT04914897CT.gov A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) | — | Terminated | — | — | — |
NCT04879849CT.gov A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers | — | Completed | — | — | — |
NCT05086692CT.gov A Beta-only IL-2 ImmunoTherapY Study | — | Recruiting | — | — | — |
NCT04964479CT.gov A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) | — | Unknown | — | — | — |
NCT04787042CT.gov Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | — | Recruiting | — | — | — |
NCT04956692CT.gov Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) | — | Active Not Recruiting | — | — | — |
NCT04968002CT.gov Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy | — | Unknown | — | — | — |
NCT04956640CT.gov Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | — | Active Not Recruiting | — | — | — |
NCT04892472CT.gov EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT04990479CT.gov Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma | — | Terminated | — | — | — |
NCT04913337CT.gov Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | — | Active Not Recruiting | — | — | — |
NCT04622007CT.gov Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) | — | Unknown | — | — | — |
NCT04746924CT.gov A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer | — | Terminated | — | — | — |
NCT04875585CT.gov Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC | — | Recruiting | — | — | — |
NCT04793815CT.gov Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE) | — | Completed | — | — | — |
NCT04725188CT.gov Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002) | — | Completed | — | — | — |
NCT04902040CT.gov Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | — | Terminated | — | — | — |
NCT04738487CT.gov Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) | — | Completed | — | — | — |
NCT04754815CT.gov Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC | — | Withdrawn | — | — | — |
NCT04393883CT.gov A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC) | — | Unknown | — | — | — |
NCT04720976CT.gov JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04725331CT.gov A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05739006CT.gov Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies | — | Unknown | — | — | — |
NCT04736173CT.gov Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04699123CT.gov The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04660929CT.gov CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | — | Unknown | — | — | — |
NCT04609566CT.gov Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors | — | Completed | — | — | — |
NCT04547504CT.gov PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % | — | Active Not Recruiting | — | — | — |
NCT04515979CT.gov Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects | — | Terminated | — | — | — |
NCT04619797CT.gov A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT04613596CT.gov Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | — | Recruiting | — | — | — |
NCT04581824CT.gov Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT04909684CT.gov Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC | — | Unknown | — | — | — |
NCT04533451CT.gov Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04585750CT.gov The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | — | Recruiting | — | — | — |
NCT04524689CT.gov Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC | — | Terminated | — | — | — |
NCT04475939CT.gov Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT04586465CT.gov Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC | — | Unknown | — | — | — |
NCT04585035CT.gov Study to Evaluate D-1553 in Subjects With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04750083CT.gov HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT04452214CT.gov A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors | — | Completed | — | — | — |
NCT04571632CT.gov Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors | — | Unknown | — | — | — |
NCT04370587CT.gov A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT04140526CT.gov Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | — | Active Not Recruiting | — | — | — |
NCT04526691CT.gov Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) | — | Active Not Recruiting | — | — | — |
NCT04114136CT.gov Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | — | Recruiting | — | — | — |
NCT04557007CT.gov Drug Concentration Monitoring of Pembrolizumab in Non-Small Cell Lung Cancer Patients | — | Terminated | — | — | — |
NCT04394624CT.gov Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) | — | Terminated | — | — | — |
NCT04432857CT.gov AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04032418CT.gov Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04222972CT.gov A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT04265534CT.gov KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC | — | Terminated | — | — | — |
NCT04561362CT.gov Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | — | Active Not Recruiting | — | — | — |
NCT04380636CT.gov Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | — | Active Not Recruiting | — | — | — |
NCT04253964CT.gov Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy | — | Recruiting | — | — | — |
NCT04274907CT.gov A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression | — | Terminated | — | — | — |
NCT04383938CT.gov Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | — | Completed | — | — | — |
NCT04120454CT.gov Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT04267848CT.gov Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | — | Recruiting | — | — | — |
NCT04332653CT.gov NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04427475CT.gov Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT04389632CT.gov A Study of Sigvotatug Vedotin in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04340882CT.gov Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade | — | Active Not Recruiting | — | — | — |
NCT04061590CT.gov Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT04396457CT.gov Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901 | — | Unknown | — | — | — |
NCT04297605CT.gov Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 | — | Recruiting | — | — | — |
NCT04344795CT.gov Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | — | Completed | — | — | — |
NCT04317534CT.gov Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm | — | Recruiting | — | — | — |
NCT04374877CT.gov Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04333004CT.gov Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy | — | Unknown | — | — | — |
NCT03996473CT.gov Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases | — | Terminated | — | — | — |
NCT04252365CT.gov Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer | — | Unknown | — | — | — |
NCT04194944CT.gov A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04007744CT.gov Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04244552CT.gov A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | — | Terminated | — | — | — |
NCT04042701CT.gov DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04139317CT.gov Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% | — | Terminated | — | — | — |
NCT04165096CT.gov KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C) | — | Completed | — | — | — |
NCT04256707CT.gov Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment | — | Completed | — | — | — |
NCT04166487CT.gov Plasma-Adapted First-Line Pembro In NSCLC | — | Active Not Recruiting | — | — | — |
NCT04187872CT.gov LITT and Pembrolizumab in Recurrent Brain Metastasis | — | Terminated | — | — | — |
NCT04165070CT.gov KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | — | Recruiting | — | — | — |
NCT04165083CT.gov KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B) | — | Completed | — | — | — |
NCT04198766CT.gov Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | — | Active Not Recruiting | — | — | — |
NCT04153734CT.gov Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC | — | Not Yet Recruiting | — | — | — |
NCT04040361CT.gov Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY) | — | Unknown | — | — | — |
NCT04164745CT.gov Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03968419CT.gov This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. | — | Terminated | — | — | — |
NCT04716933CT.gov Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study | — | Completed | — | — | — |
NCT04676412CT.gov Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study | — | Completed | — | — | — |
NCT04032704CT.gov A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03991819CT.gov Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT04083599CT.gov GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04027946CT.gov LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT03970746CT.gov Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC | — | Active Not Recruiting | — | — | — |
NCT04044859CT.gov ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | — | Active Not Recruiting | — | — | — |
NCT04060342CT.gov GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | — | Terminated | — | — | — |
NCT03546361CT.gov CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04032847CT.gov ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC | — | Terminated | — | — | — |
NCT04291755CT.gov Development and Analysis of a Stool Bank for Cancer Patients | — | Recruiting | — | — | — |
NCT03976323CT.gov Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) | — | Completed | — | — | — |
NCT03948763CT.gov A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) | — | Terminated | — | — | — |
NCT03976375CT.gov Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) | — | Completed | — | — | — |
NCT03924869CT.gov Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867) | — | Terminated | — | — | — |
NCT04234113CT.gov Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT03849469CT.gov A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors | — | Completed | — | — | — |
NCT03971474CT.gov Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) | — | Completed | — | — | — |
NCT03474497CT.gov UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | — | Active Not Recruiting | — | — | — |
NCT03881488CT.gov Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies | — | Completed | — | — | — |
NCT03645928CT.gov Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | — | Terminated | — | — | — |
NCT03166254CT.gov Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT03647163CT.gov Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03793179CT.gov Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT03846310CT.gov A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer | — | Completed | — | — | — |
NCT03829319CT.gov Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006) | — | Completed | — | — | — |
NCT03829332CT.gov Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007) | — | Completed | — | — | — |
NCT03625323CT.gov Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC | — | Completed | — | — | — |
NCT03574220CT.gov Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT03841110CT.gov FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03847519CT.gov Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03732274CT.gov Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC | — | Completed | — | — | — |
NCT03715205CT.gov Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) | — | Completed | — | — | — |
NCT03809624CT.gov Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer | — | Terminated | — | — | — |
NCT03476681CT.gov Study of NEO-201 in Solid Tumors Expansion Cohorts | — | Recruiting | — | — | — |
NCT03589339CT.gov NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | — | Active Not Recruiting | — | — | — |
NCT03735290CT.gov A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer | — | Terminated | — | — | — |
NCT03637803CT.gov Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors | — | Terminated | — | — | — |
NCT03417882CT.gov GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC | — | Terminated | — | — | — |
NCT03559049CT.gov Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03631199CT.gov Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects | — | Terminated | — | — | — |
NCT03836352CT.gov Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03775850CT.gov A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | — | Completed | — | — | — |
NCT03228667CT.gov QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | — | Active Not Recruiting | — | — | — |
NCT03634241CT.gov Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study | — | Completed | — | — | — |
NCT03621982CT.gov Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03769129CT.gov Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC | — | Recruiting | — | — | — |
NCT03656094CT.gov Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors | — | Unknown | — | — | — |
NCT03664024CT.gov Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) | — | Completed | — | — | — |
NCT03631784CT.gov A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799) | — | Completed | — | — | — |
NCT05226728CT.gov Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung Cancer | — | Completed | — | — | — |
NCT03631706CT.gov M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT03516981CT.gov A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) | — | Completed | — | — | — |
NCT03732664CT.gov ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer | — | Completed | — | — | — |
NCT03412877CT.gov Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer | — | Recruiting | — | — | — |
NCT03523702CT.gov The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial | — | Completed | — | — | — |
NCT03633110CT.gov Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | — | Completed | — | — | — |
NCT03236935CT.gov Phase Ib of L-NMMA and Pembrolizumab | — | Completed | — | — | — |
NCT03562871CT.gov IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC | — | Completed | — | — | — |
NCT03590054CT.gov Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | — | Completed | — | — | — |
NCT03396497CT.gov Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03515629CT.gov REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer | — | Terminated | — | — | — |
NCT03515837CT.gov Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789) | — | Completed | — | — | — |
NCT03299088CT.gov Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations | — | Completed | — | — | — |
NCT03485209CT.gov Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03425006CT.gov Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03197467CT.gov Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT03556228CT.gov VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | — | Recruiting | — | — | — |
NCT04670107CT.gov The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy | — | Completed | — | — | — |
NCT03447678CT.gov Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors. | — | Unknown | — | — | — |
NCT03520686CT.gov Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03134456CT.gov Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX | — | Completed | — | — | — |
NCT03380871CT.gov A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer | — | Completed | — | — | — |
NCT03526835CT.gov A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT03454451CT.gov CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | — | Completed | — | — | — |
NCT03425643CT.gov Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) | — | Active Not Recruiting | — | — | — |
NCT03233724CT.gov Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas | — | Terminated | — | — | — |
NCT03473925CT.gov Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | — | Completed | — | — | — |
NCT03265080CT.gov A Study of ADXS-NEO Expressing Personalized Tumor Antigens | — | Terminated | — | — | — |
NCT03382899CT.gov Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03511391CT.gov CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors | — | Completed | — | — | — |
NCT03446911CT.gov Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery | — | Unknown | — | — | — |
NCT03436056CT.gov PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients | — | Terminated | — | — | — |
NCT03396445CT.gov Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) | — | Completed | — | — | — |
NCT03225664CT.gov Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced | — | Active Not Recruiting | — | — | — |
NCT03774732CT.gov PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT03379441CT.gov Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC | — | Unknown | — | — | — |
NCT03302234CT.gov Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598) | — | Completed | — | — | — |
NCT03307759CT.gov Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma | — | Terminated | — | — | — |
NCT03329950CT.gov A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | — | Completed | — | — | — |
NCT03087760CT.gov Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03311672CT.gov T-Cell PET Imaging With [18F]F-AraG in Lung Cancer | — | Withdrawn | — | — | — |
NCT03373955CT.gov A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients | — | Unknown | — | — | — |
NCT03325166CT.gov Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases | — | Terminated | — | — | — |
NCT03157089CT.gov Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung | — | Completed | — | — | — |
NCT03217071CT.gov Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03411473CT.gov Study of AGEN1884 With Pembrolizumab in 1L NSCLC | — | Terminated | — | — | — |
NCT03229278CT.gov Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | — | Completed | — | — | — |
NCT03242915CT.gov Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents | — | Completed | — | — | — |
NCT03184571CT.gov Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT03257722CT.gov Pembrolizumab + Idelalisib for Lung Cancer Study | — | Terminated | — | — | — |
NCT03224871CT.gov UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC. | — | Completed | — | — | — |
NCT02824965CT.gov Pembrolizumab + CVA21 in Advanced NSCLC | — | Unknown | — | — | — |
NCT03245177CT.gov Pembrolizumab in Combination With Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Withdrawn | — | — | — |
NCT02758587CT.gov Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | — | Unknown | — | — | — |
NCT03004183CT.gov SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC | — | Completed | — | — | — |
NCT03138889CT.gov Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT03050060CT.gov Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer | — | Terminated | — | — | — |
NCT02658097CT.gov Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC | — | Completed | — | — | — |
NCT02987998CT.gov Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC | — | Terminated | — | — | — |
NCT03875092CT.gov A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study | — | Completed | — | — | — |
NCT03137771CT.gov Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT02963610CT.gov Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03083808CT.gov Phase II Trial of Continuation Therapy in Advanced NSCLC | — | Completed | — | — | — |
NCT02949843CT.gov Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations | — | Terminated | — | — | — |
NCT03049618CT.gov Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 | — | Completed | — | — | — |
NCT02879760CT.gov Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients | — | Completed | — | — | — |
NCT02952989CT.gov A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03053856CT.gov Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients | — | Unknown | — | — | — |
NCT02998567CT.gov Combination Study of Guadecitabine/ASTX727 and Pembrolizumab | — | Active Not Recruiting | — | — | — |
NCT03035890CT.gov Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03065764CT.gov 89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer | — | Unknown | — | — | — |
NCT03293680CT.gov Pembrolizumab in Elderly Patients With Advanced Lung Cancer | — | Completed | — | — | — |
NCT02938624CT.gov Anti PD-1 Neo-adjuvant Treatment for NSCLC | — | Completed | — | — | — |
NCT02733159CT.gov Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2 | — | Completed | — | — | — |
NCT02661100CT.gov A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | — | Withdrawn | — | — | — |
NCT04076228CT.gov Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients | — | Completed | — | — | — |
NCT02818920CT.gov Neoadjuvant Pembrolizumab | — | Completed | — | — | — |
NCT02955290CT.gov CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer | — | Active Not Recruiting | — | — | — |
NCT02840994CT.gov A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02779751CT.gov A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02922764CT.gov A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer | — | Completed | — | — | — |
NCT02760225CT.gov Pembrolizumab-PET Imaging | — | Completed | — | — | — |
NCT02858869CT.gov Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | — | Completed | — | — | — |
NCT02955758CT.gov Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT02909452CT.gov Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT02879994CT.gov Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02684461CT.gov Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel | — | Completed | — | — | — |
NCT02864394CT.gov Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033) | — | Completed | — | — | — |
NCT02862457CT.gov Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434) | — | Completed | — | — | — |
NCT02621398CT.gov Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02835690CT.gov Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032) | — | Completed | — | — | — |
NCT03850444CT.gov Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study | — | Completed | — | — | — |
NCT02581943CT.gov Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT02432963CT.gov Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | — | Active Not Recruiting | — | — | — |
NCT02775435CT.gov A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) | — | Completed | — | — | — |
NCT02710396CT.gov Genetic Predictors of Benefit to Pembrolizumab | — | Terminated | — | — | — |
NCT02575404CT.gov GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients | — | Completed | — | — | — |
NCT02681549CT.gov Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT02705820CT.gov Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy | — | Completed | — | — | — |
NCT02713529CT.gov Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer | — | Completed | — | — | — |
NCT02595866CT.gov Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | — | Completed | — | — | — |
NCT02638090CT.gov Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) | — | Active Not Recruiting | — | — | — |
NCT03950674CT.gov Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study | — | Completed | — | — | — |
NCT02578680CT.gov Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) | — | Completed | — | — | — |
NCT02504372CT.gov Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) | — | Completed | — | — | — |
NCT02563548CT.gov A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors | — | Completed | — | — | — |
NCT02546986CT.gov Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT02511184CT.gov Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients | — | Terminated | — | — | — |
NCT02364609CT.gov Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib | — | Completed | — | — | — |
NCT02444741CT.gov Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT02451930CT.gov A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC | — | Completed | — | — | — |
NCT02437136CT.gov Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) | — | Completed | — | — | — |
NCT02443324CT.gov A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer | — | Completed | — | — | — |
NCT02452424CT.gov A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | — | Terminated | — | — | — |
NCT02475213CT.gov Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer | — | Completed | — | — | — |
NCT02492568CT.gov Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC | — | Completed | — | — | — |
NCT02419495CT.gov Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT02448303CT.gov Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT02439450CT.gov A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02343952CT.gov Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC | — | Completed | — | — | — |
NCT02376699CT.gov Safety Study of SEA-CD40 in Cancer Patients | — | Terminated | — | — | — |
NCT02346955CT.gov Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | — | Terminated | — | — | — |
NCT02316002CT.gov Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02220894CT.gov Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) | — | Completed | — | — | — |
NCT02194738CT.gov Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | — | Active Not Recruiting | — | — | — |
NCT02142738CT.gov Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) | — | Completed | — | — | — |
NCT02079636CT.gov A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT02007070CT.gov Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025) | — | Completed | — | — | — |
NCT02039674CT.gov A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) | — | Completed | — | — | — |
NCT02043665CT.gov CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200) | — | Completed | — | — | — |
NCT02009449CT.gov A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01905657CT.gov Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010) | — | Completed | — | — | — |
NCT01840579CT.gov Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) | — | Completed | — | — | — |
NCT06585189CT.gov CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4] | — | Completed | — | — | — |
NCT06607393CT.gov CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3] | — | Completed | — | — | — |
NCT00098085CT.gov Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | City of Hope Medical Center | Approved | BB · 69 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →